Shark cartilage: An evidence-based systematic review for the natural standard research collaboration

Catherine Ulbricht, Ethan Basch, Ernie Paul Barrette, Stephen Bent, Heather Boon, Paul Graves Hammerness, Michael Smith, David Sollars, Philippe Szapary, Samuel H. Basch, Candy Tsourounis, Dana Hackman

Research output: Contribution to journalReview articlepeer-review

Abstract

Shark cartilage has become one of the most commonly recognized supplements in the United States. Growing interest in the shark cartilage derivative AE-941 (Neovastat, Aeterna Laboratories Inc., Canada) occurred when preclinical studies demonstrated antiangiogenic, antitumor, and antiinflammatory properties. Several clinical trials have been conducted using AE-941, and the US Food and Drug Administration granted orphan drug status to the agent in 2002. However, there is currently insufficient evidence in humans to recommend for or against shark cartilage use for any indication.

Original languageEnglish
Pages (from-to)99-111
Number of pages13
JournalJournal of Cancer Integrative Medicine
Volume3
Issue number3
StatePublished - Dec 1 2005
Externally publishedYes

Keywords

  • AE-941
  • Cartilage
  • Haifischknorpel
  • Houtsmuller Diet
  • Neovastat
  • Shark
  • Shark fin soup
  • Squalamine
  • U-955

Fingerprint Dive into the research topics of 'Shark cartilage: An evidence-based systematic review for the natural standard research collaboration'. Together they form a unique fingerprint.

Cite this